Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.71
ISIS's Cash to Debt is ranked higher than
63% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. ISIS: 2.71 )
ISIS' s 10-Year Cash to Debt Range
Min: 0.24   Max: 7.99
Current: 2.71

0.24
7.99
Equity to Asset 0.45
ISIS's Equity to Asset is ranked higher than
58% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ISIS: 0.45 )
ISIS' s 10-Year Equity to Asset Range
Min: -0.85   Max: 0.76
Current: 0.45

-0.85
0.76
F-Score: 4
Z-Score: 3.45
M-Score: 2.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -35.08
ISIS's Operating margin (%) is ranked higher than
75% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. ISIS: -35.08 )
ISIS' s 10-Year Operating margin (%) Range
Min: -438.91   Max: -12.18
Current: -35.08

-438.91
-12.18
Net-margin (%) -41.17
ISIS's Net-margin (%) is ranked higher than
73% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. ISIS: -41.17 )
ISIS' s 10-Year Net-margin (%) Range
Min: -334.33   Max: 127.52
Current: -41.17

-334.33
127.52
ROE (%) -16.03
ISIS's ROE (%) is ranked higher than
74% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. ISIS: -16.03 )
ISIS' s 10-Year ROE (%) Range
Min: -7400   Max: 53.16
Current: -16.03

-7400
53.16
ROA (%) -7.16
ISIS's ROA (%) is ranked higher than
78% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. ISIS: -7.16 )
ISIS' s 10-Year ROA (%) Range
Min: -68.37   Max: 23.6
Current: -7.16

-68.37
23.6
ROC (Joel Greenblatt) (%) -59.94
ISIS's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. ISIS: -59.94 )
ISIS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -911.25   Max: -59.94
Current: -59.94

-911.25
-59.94
Revenue Growth (%) 6.90
ISIS's Revenue Growth (%) is ranked higher than
81% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. ISIS: 6.90 )
ISIS' s 10-Year Revenue Growth (%) Range
Min: -39.4   Max: 83.7
Current: 6.9

-39.4
83.7
EBITDA Growth (%) -4.50
ISIS's EBITDA Growth (%) is ranked higher than
78% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. ISIS: -4.50 )
ISIS' s 10-Year EBITDA Growth (%) Range
Min: -49.6   Max: 61.3
Current: -4.5

-49.6
61.3
EPS Growth (%) -3.90
ISIS's EPS Growth (%) is ranked higher than
81% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. ISIS: -3.90 )
ISIS' s 10-Year EPS Growth (%) Range
Min: -71.2   Max: 117.8
Current: -3.9

-71.2
117.8
» ISIS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ISIS Guru Trades in Q2 2013

Jim Simons 27,914 sh (New)
Steven Cohen 27,107 sh (+39.49%)
Murray Stahl 17,000 sh (unchged)
Louis Moore Bacon Sold Out
» More
Q3 2013

ISIS Guru Trades in Q3 2013

Jim Simons 328,914 sh (+1078.31%)
Steven Cohen 67,399 sh (+148.64%)
Murray Stahl 17,000 sh (unchged)
» More
Q4 2013

ISIS Guru Trades in Q4 2013

Murray Stahl 17,000 sh (unchged)
Jim Simons 326,114 sh (-0.85%)
Steven Cohen 8,531 sh (-87.34%)
» More
Q1 2014

ISIS Guru Trades in Q1 2014

George Soros 5,539 sh (New)
Ron Baron 45,251 sh (New)
Steven Cohen 74,106 sh (+768.67%)
Murray Stahl 17,000 sh (unchged)
Jim Simons 136,914 sh (-58.02%)
» More
» Details

Insider Trades

Latest Guru Trades with ISIS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2014-03-31 New Buy0.01%$38.56 - $59 $ 31.62-34%45251
George Soros 2014-03-31 New Buy$38.56 - $59 $ 31.62-34%5539
George Soros 2011-06-30 Sold Out $8.54 - $9.38 $ 31.62254%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.00
ISIS's P/B is ranked higher than
62% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. ISIS: 10.00 )
ISIS' s 10-Year P/B Range
Min: 3   Max: 1710
Current: 10

3
1710
P/S 27.50
ISIS's P/S is ranked higher than
68% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. ISIS: 27.50 )
ISIS' s 10-Year P/S Range
Min: 4.33   Max: 84.47
Current: 27.5

4.33
84.47
PFCF 98.60
ISIS's PFCF is ranked higher than
90% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ISIS: 98.60 )
ISIS' s 10-Year PFCF Range
Min: 3.7   Max: 198.35
Current: 98.6

3.7
198.35
EV-to-EBIT -37.25
ISIS's EV-to-EBIT is ranked higher than
65% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ISIS: -37.25 )
ISIS' s 10-Year EV-to-EBIT Range
Min: 395.6   Max: 596.9
Current: -37.25

395.6
596.9
Current Ratio 7.16
ISIS's Current Ratio is ranked higher than
84% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. ISIS: 7.16 )
ISIS' s 10-Year Current Ratio Range
Min: 2.49   Max: 9.89
Current: 7.16

2.49
9.89
Quick Ratio 7.09
ISIS's Quick Ratio is ranked higher than
84% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. ISIS: 7.09 )
ISIS' s 10-Year Quick Ratio Range
Min: 2.49   Max: 9.89
Current: 7.09

2.49
9.89

Valuation & Return

vs
industry
vs
history
Price/Net Cash 21.80
ISIS's Price/Net Cash is ranked higher than
76% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. ISIS: 21.80 )
ISIS' s 10-Year Price/Net Cash Range
Min: 4.75   Max: 403.13
Current: 21.8

4.75
403.13
Price/Net Current Asset Value 20.40
ISIS's Price/Net Current Asset Value is ranked higher than
75% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. ISIS: 20.40 )
ISIS' s 10-Year Price/Net Current Asset Value Range
Min: 4.69   Max: 844.5
Current: 20.4

4.69
844.5
Price/Tangible Book 10.40
ISIS's Price/Tangible Book is ranked higher than
68% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. ISIS: 10.40 )
ISIS' s 10-Year Price/Tangible Book Range
Min: 1.83   Max: 216.67
Current: 10.4

1.83
216.67
Price/Median PS Value 2.60
ISIS's Price/Median PS Value is ranked higher than
68% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. ISIS: 2.60 )
ISIS' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 6.05
Current: 2.6

0.24
6.05
Forward Rate of Return (Yacktman) -1.24
ISIS's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. ISIS: -1.24 )
ISIS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8.8   Max: -6.4
Current: -1.24

-8.8
-6.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ISI.Germany
Isis Pharmaceuticals was incorporated in California on January 10, 1989, and reorganized as a Delaware corporation in April 1991. The Company is engaged in antisense drug discovery and development, exploiting a novel drug discovery platform it created to generate a pipeline of first-in-class drugs. Antisense technology provides a direct route from genomics to drugs. Its flagship product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia, or HoFH. Patients with HoFH are at high cardiovascular risk and cannot reduce their low-density lipoprotein cholesterol, or LDL-C, sufficiently with currently available lipid-lowering therapies. The Company has a pipeline of 28 drugs in development that represents the potential for significant commercial opportunities in many therapeutic areas. It was successful in bringing KYNAMRO to the market for patients with HoFH. These patients are at high cardiovascular risk and may not be able to reduce their LDL-C sufficiently with currently available lipid-lowering therapies. In addition to KYNAMRO, many of the other drugs in its pipeline are demonstrating encouraging clinical activity in a variety of diseases. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state and local regulations.
» More Articles for ISIS

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Keynote Systems Inc., Isis Pharmaceuticals, Coleman Cable Inc. Jul 01 2013 
Isis Pharmaceuticals Inc. (ISIS) Director, COO B Lynne Parshall sells 17,200 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. (ISIS) Chairman, President, CEO Stanley T Crooke sells 32,000 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
Guru Stocks at 52-Week Low: The Dun & Bradstreet Corp, FTI Consulting Inc, Terra Nitrogen Company L. Mar 07 2010 
Guru Stocks at 52-Week Low: Dun & Bradstreet Corp, GameStop Corp, Dean Foods Company, SunPower Corp, Feb 21 2010 
Weekly Guru Bargains Highlights: Weatherford International, MetroPCS Communications, Isis Pharmaceut Feb 13 2010 
Weekly Guru Bargain Highlights: Sohu.com Inc, Isis Pharmaceuticals Inc, Netease.com Inc, Barclays PL Feb 06 2010 
Weekly Guru Bargains Highlights: Isis Pharmaceuticals Inc, MetroPCS Communications Inc, American Int Jan 09 2010 

More From Our Partners
Isis Pharma Initiates Phase II Study on ISIS-APO(a) - Analyst Blog Jul 21 2014 - ZACKS

More From Other Websites
Nasdaq stocks posting largest percentage increases Jul 29 2014
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call Jul 28 2014
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call Jul 28 2014
Isis Pharma Initiates Phase II Study on ISIS-APO(a) Jul 21 2014
Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a) Jul 17 2014
Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a) Jul 17 2014
Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx Jul 16 2014
Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx Jul 16 2014
What happens when free-speech engines like Twitter and Facebook become megaphones for violence? Jul 15 2014
Cramer's Lightning Round - BioMarin Deserves To Be Higher (7/14/14) Jul 15 2014
Markets Edge Higher; Alcoa Profit Beats Street View Jul 09 2014
One sign mobile payments aren’t working? Militant groups have better brand recognition Jul 07 2014
Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program Jul 02 2014
Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program Jul 02 2014
Isis - Addressing Some Of The Bull Arguments To My Short Thesis Jul 01 2014
Isis: Long-Term Kynamro Adverse Events May Apply To Entire ISIS 2.0 Pipeline Jun 26 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide